An update from TNF Pharmaceuticals ( (TNFA) ) is now available.
On March 6, 2025, TNF Pharmaceuticals held a telephonic conference call to discuss the progress of their lead compound, Isomyosamine. The company provided updates on their research and development efforts, but emphasized that the information shared is not necessarily material or required to be disclosed under regulatory obligations.
More about TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the research and development of medical compounds, with a primary emphasis on their lead compound, Isomyosamine.
YTD Price Performance: -67.83%
Average Trading Volume: 537,931
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.02M
Find detailed analytics on TNFA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com